Madhu Mazumdar

发表

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract

H. Scher, D. Bajorin, J. McCaffrey, 2000, Cancer.

Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update

N. Kemeny, J. Bertino, E. Sigurdson, 1994, Cancer.

Evaluation of Drug Delivery and Survival Impact of Dose-Intense Relative to Conventional-Dose Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy in Urothelial Cancer

M. Mazumdar, H. Scher, D. Bajorin, 2000, Cancer investigation.

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

M. Mazumdar, H. Scher, D. Bajorin, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

M Mazumdar, S D Fossa, S. Fosså, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.

Joseph, Bertino, M Mazumdar, 1995, Blood.

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

M. Mazumdar, H. Scher, D. Bajorin, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.

M Mazumdar, G. Demetri, M. Mazumdar, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.

L. Schwartz, M. Mazumdar, H. Scher, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments.

M. Mazumdar, J. Glassman, Madhu Mazumdar, 2000, Statistics in medicine.

Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.

J. Bacik, M. Mazumdar, H. Scher, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center.

M. Mazumdar, R. Motzer, D. Bajorin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trials in relapsed prostate cancer: defining the target.

M Mazumdar, M. Mazumdar, H. Scher, 1996, Journal of the National Cancer Institute.

Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer

M. Mazumdar, B. Usmani, D. Nanus, 2000, British Journal of Cancer.

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.

M. Mazumdar, H. Scher, D. Pfister, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse, and second primary tumors.

M. Mazumdar, P. Borgen, B. McCormick, 1992, International journal of radiation oncology, biology, physics.